1. Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis.
- Author
-
Han JM, Oh KY, Choi SJ, Lee WW, Jin BH, Kim JH, Yu HJ, Kim RJY, Yoon HJ, Lee JI, Hong SD, and Cho SD
- Subjects
- Humans, Animals, Cell Line, Tumor, Mice, Mice, Nude, Apoptosis drug effects, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Female, Male, Mutation genetics, Mice, Inbred BALB C, Protein Kinase Inhibitors pharmacology, Gene Expression Regulation, Neoplastic drug effects, Myeloid Cell Leukemia Sequence 1 Protein metabolism, Myeloid Cell Leukemia Sequence 1 Protein genetics, TOR Serine-Threonine Kinases metabolism, Afatinib pharmacology, Afatinib therapeutic use, ErbB Receptors metabolism, Signal Transduction drug effects, Mouth Neoplasms drug therapy, Mouth Neoplasms genetics, Mouth Neoplasms metabolism, Mouth Neoplasms pathology, Xenograft Model Antitumor Assays
- Abstract
Purpose: This study investigates the role and effectiveness of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in oral cancer, focusing on the clinical relevance of EGFR and myeloid cell leukemia-1 (Mcl-1) in head and neck cancers (HNCs). It aims to explore the molecular mechanism of afatinib, a TKI, in treating human oral cancer., Methods: We conducted an in silico analysis using databases like The Cancer Genome Atlas, Gene Expression Omnibus, and Clinical Proteomic Tumor Analysis Consortium, along with immunohistochemistry staining, to study EGFR and Mcl-1 expression in HNCs. For investigating afatinib's anticancer properties, we performed various in vitro and in vivo analyses, including trypan blue exclusion assay, Western blotting, 4'-6-diamidino-2-phenylindole staining, flow cytometry, quantitative real-time PCR, Mitochondrial membrane potential assay, overexpression vector construction, transient transfection, and a tumor xenograft model., Results: Higher expression levels of EGFR and Mcl-1 were observed in HNC patient tissues compared to normal tissues, with their co-expression significantly linked to poor prognosis. There was a strong correlation between EGFR and Mcl-1 expressions in oral cancer patients. Afatinib treatment induced apoptosis and suppressed Mcl-1 in oral cancer cell lines without the EGFR T790M mutation. The mechanism of afatinib-induced apoptosis involved the EGFR/mTOR/Mcl-1 axis, as shown by the effects of mTOR activator MHY1485 and inhibitor rapamycin. Afatinib also increased Bim expression, mitochondrial membrane permeabilization, and cytochrome c release. It significantly lowered tumor volume without affecting body, liver, and kidney weights., Conclusion: Afatinib, targeting the EGFR/mTOR/Mcl-1 axis, shows promise as a therapeutic strategy for oral cancer, especially in patients with high EGFR and Mcl-1 expressions., Competing Interests: Declarations. Ethics approval and consent to participate: All procedures for clinical samples were performed after obtaining approval from the Institutional Review Board of the Seoul National University Dental Hospital (IRB No. ERI20021). Consent to publish: All authors provided their consent for publication. Competing interests: The authors have no competing interests to declare that are relevant to the content of this article., (© 2024. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF